These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31218458)

  • 1. Cost Comparison of Benign Prostatic Hyperplasia Treatment Options.
    DeWitt-Foy ME; Gill BC; Ulchaker JC
    Curr Urol Rep; 2019 Jun; 20(8):45. PubMed ID: 31218458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room.
    Gill BC; Ulchaker JC
    Curr Urol Rep; 2018 Jul; 19(9):72. PubMed ID: 30022307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis.
    Davis NF; Jack GS; Witjes WP; Bjartell A; Caris C; Patel A; de la Taille A; Lawrentschuk N; Bolton DM; Tubaro A
    World J Urol; 2019 May; 37(5):873-878. PubMed ID: 30145778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Office-Based HE-TUMT Costs Less than Medication over Four Years in Treating Benign Prostatic Hyperplasia.
    Lerner LB; Thurmond P; Harsch MR; Martinson MS
    Surg Technol Int; 2015 May; 26():182-9. PubMed ID: 26055008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of benign prostatic hyperplasia treatment: a literature review.
    Kortt MA; Bootman JL
    Clin Ther; 1996; 18(6):1227-41. PubMed ID: 9001839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation.
    Bellinger AS; Elliott SP; Yang L; Wei JT; Saigal CS; Smith A; Wilt TJ; Strope SA;
    J Urol; 2012 May; 187(5):1739-46. PubMed ID: 22425128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data.
    Ahn HS; Kim SJ; Choi JB; Choo SH; Shim KH; Kim SI
    BJU Int; 2019 May; 123(5A):E79-E85. PubMed ID: 30303597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.
    Naslund MJ; Carlson AM; Williams MJ
    J Urol; 2005 Jun; 173(6):2090-3; discussion 2093. PubMed ID: 15879849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economics of different treatment options of benign prostatic hyperplasia in Turkey.
    Ilker Y; Tarcan T; Akdaş A
    Int Urol Nephrol; 1996; 28(4):525-8. PubMed ID: 9119638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
    Speakman M; Kirby R; Doyle S; Ioannou C
    BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness in the management of benign prostatic hyperplasia: Italian data.
    Di Silverio F; D'Eramo G; Flammia GP; Sciarra A; Buscarini M; Mauro M; Sciarra F
    Minerva Urol Nefrol; 1994 Jun; 46(2):93-9. PubMed ID: 7526475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Outcomes of Medical Management and Minimally Invasive Surgical Techniques for Lower Urinary Tract Symptoms due to BPH.
    Sterling J; Farber N; Gupta NK
    Curr Urol Rep; 2019 Apr; 20(6):29. PubMed ID: 30989392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods.
    Ackerman SJ; Rein AL; Blute M; Beusterien K; Sullivan EM; Tanio CP; Manyak MJ; Strauss MJ
    Urology; 2000 Dec; 56(6):972-80. PubMed ID: 11113743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated total costs of treating benign prostatic hyperplasia in Sweden.
    Ahlstrand C; Carlsson P; Jönsson B
    Scand J Urol Nephrol; 1995 Mar; 29(1):57-63. PubMed ID: 7542399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Benign Prostatic Hyperplasia in Older Adults.
    Woodard TJ; Manigault KR; McBurrows NN; Wray TL; Woodard LM
    Consult Pharm; 2016; 31(8):412-24. PubMed ID: 27535076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of alpha blocker treatments for benign prostatic hyperplasia in Medicare beneficiaries.
    Sidi Y; Duan Y; Rhee TG; Wu ZH
    Res Social Adm Pharm; 2021 Jun; 17(6):1119-1139. PubMed ID: 32891534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.